Paper Details

  1. Home
  2. Paper Details

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.

Author: ChaturvediSoumya A, ChildressAnn, CutlerAndrew J, FryNicholas, HullJoseph T, KosheleffAlisa R, LiransoTesfaye, NasserAzmi, OdeboOyinkansola, RubinJonathan, SchwabeStefan

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Viloxazine extended-release capsules (viloxazine ER) have shown efficacy and safety in treating attention-deficit/hyperactivity disorder (ADHD) in children. This study aimed to evaluate the efficacy and safety of viloxazine ER in adults with ADHD.
Paper Details　
Original Abstract of the Article :
Label="BACKGROUND AND OBJECTIVE">Attention-deficit/hyperactivity disorder is a neurodevelopmental disorder that typically begins in childhood and often persists into adulthood. Recent phase III trials have demonstrated the efficacy and safety of viloxazine extended-release capsules (viloxazine ER; Q...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328182/

データ提供：米国国立医学図書館（NLM）

Viloxazine for Adult ADHD: A New Oasis in the Desert of Treatment Options

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder, and finding effective treatment for adults with ADHD can be a challenging journey, like navigating a vast and unforgiving desert. This study, published in the field of

psychiatry

, investigates the efficacy and safety of viloxazine extended-release capsules (viloxazine ER) in adults with ADHD. The researchers explored the potential of viloxazine ER to manage ADHD symptoms in adults.

A Potential New Treatment for Adult ADHD

The study found that viloxazine ER was effective in improving ADHD symptoms in adults, offering a potential new treatment option for this challenging condition. It's like discovering a new oasis in the desert of ADHD treatments, offering a potential source of relief and improved quality of life for those struggling with ADHD.

Finding Relief in the Desert

This research is a promising development for adults with ADHD, offering a potential new treatment option that could lead to a more fulfilling and productive life. Like a camel finding a source of water in a parched desert, viloxazine ER could offer a much-needed reprieve from the challenges of ADHD.

Dr. Camel's Conclusion

This study, like a caravan discovering a new oasis in the desert, suggests that viloxazine ER may be a valuable tool for treating ADHD in adults. This research offers a potential path to greater well-being and control for those struggling with ADHD, offering a chance to thrive despite the challenges of this condition. It's a reminder that even in the seemingly barren desert of ADHD treatment, there can be hidden oases of hope and relief.

Date :
  1. Date Completed 2022-08-04
  2. Date Revised 2023-01-25
Further Info :

Pubmed ID

35896943

DOI: Digital Object Identifier

PMC9328182

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.